Resmed (RSMDF) Receivables - Other (2018 - 2026)

Resmed (RSMDF) has reported Receivables - Other for 9 consecutive years, with $48.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Other fell 4.8% year-over-year to $48.7 million; the trailing twelve-month figure through Jun 2026 stood at $48.7 million (down 4.8% YoY), and the FY2026 full-year result was $48.7 million, down 4.8% from the prior year.
• Receivables - Other improved to $48.7 million in Q2 2026 per RSMDF's latest filing, from $47.1 million in the prior quarter.
• Across five years, Receivables - Other topped out at $61.4 million in Q4 2025 and bottomed at $23.1 million in Q4 2022.
• Historically, Receivables - Other has averaged $39.0 million across 5 years, with a median of $38.1 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Receivables - Other surged 135.86% in 2022, then fell 8.77% in 2026.
• Over 5 years, Receivables - Other stood at $23.1 million in 2022, then soared by 49.62% to $34.6 million in 2023, then surged by 35.98% to $47.0 million in 2024, then surged by 30.61% to $61.4 million in 2025, then declined by 20.66% to $48.7 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $48.7 million, $47.1 million, and $61.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.